NASDAQ:CTOR Citius Oncology Q4 2025 Earnings Results & Report $0.56 +0.01 (+1.79%) Closing price 04:00 PM EasternExtended Trading$0.55 -0.01 (-0.97%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Citius Oncology met analyst earnings expectations in its Q4 2025 results, released December 23, 2025. The company reported EPS of -$0.06 versus the -$0.06 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateDecember 23, 2025TimeBefore Market OpensConference Call7:00 AM ET Citius Oncology EPS ResultsActual EPS-$0.06Consensus EPS -$0.06Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate0 of last 5 quartersCitius Oncology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCitius Oncology's Q4 2026 earnings is estimated for Thursday, December 17, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 23, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Citius Oncology Q4 2025 Earnings FAQ Did Citius Oncology beat earnings estimates for Q4 2025? Citius Oncology (NASDAQ:CTOR) reported earnings of -$0.06 per share for Q4 2025, matching the consensus estimate of -$0.06. The report was announced on Tuesday, December 23, 2025. When is Citius Oncology's next earnings date? Citius Oncology's next earnings date is estimated for Thursday, December 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Citius Oncology on the company's earnings history page. Citius Oncology Earnings HeadlinesCitius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in LondonNovember 11, 2026 | prnewswire.comCitius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in EuropeNovember 4, 2026 | prnewswire.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 18 at 1:00 AM | Base Camp Trading (Ad)Citius Oncology, Inc.: Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the Fiscal Fourth Quarter ...October 26, 2026 | finanznachrichten.deCitius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026October 26, 2026 | prnewswire.comCitius Pharmaceuticals to Participate in October 2026 Investor ConferencesOctober 12, 2026 | prnewswire.comSee More Citius Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Oncology and other key companies, straight to your email. Email Address About Citius OncologyCitius Oncology (NASDAQ:CTOR) is a biopharmaceutical company focused on developing and commercializing oncology therapies. Its lead product is LYMPHIR (denileukin diftitox-cxdl), an immunotherapy approved in the United States for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. LYMPHIR targets cells expressing the interleukin-2 receptor and is intended to treat certain forms of CTCL, a rare non-Hodgkin lymphoma that affects the skin. The company’s commercial activities are centered on making the therapy available to eligible patients in the U.S. Citius Oncology became a publicly traded company following a business combination involving Citius Pharmaceuticals’ oncology subsidiary and TenX Keane Acquisition. Leonard Mazur, a co-founder and longtime executive of Citius Pharmaceuticals, has served as Citius Oncology’s chief executive officer.View Citius Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.